Keyphrases
Action Outcome
22%
Actual Performance
16%
Age-related
16%
Age-related Differences
20%
Aging
20%
Alien Limb
40%
Apathy
50%
Apraxia
23%
Atomoxetine
22%
Attenuation
20%
Bayesian Modeling
19%
Brain Activity
25%
Clozapine
21%
Cognitive Ability
20%
Cognitive Impairment
19%
Cognitive Neuroscience
18%
Corticobasal Syndrome
33%
Disease Severity
37%
Dopamine
38%
Dopaminergic Modulation
16%
Dose Equivalent
24%
Frontostriatal Circuits
18%
Goal Intention
16%
Goal-directed Behavior
40%
Inhibitory Control
50%
Intentional Binding
28%
Interval Sensitivity
16%
Levodopa Therapy
24%
Libet
16%
Locus Coeruleus
42%
Motivation
47%
Negative Symptoms
50%
Noradrenergic
45%
Older Adults
37%
Parkinson's Disease
100%
Phenomenological Characteristics
16%
Prefrontal Networks
16%
Premature Response
16%
Prior Beliefs
18%
Reduced Precision
20%
Response Inhibition
22%
Sedation
19%
Self-generated
22%
Sensorimotor Prediction
20%
Sensory Attenuation
33%
Supplementary Motor Area
38%
Trait Optimism
22%
Urge to Move
16%
Visuomotor Task
26%
Voluntary Action
27%
Neuroscience
Apraxia
33%
Atomoxetine
26%
Behavior (Neuroscience)
10%
Brain Network
33%
Cerebellum
8%
Clozapine
21%
Cognitive Change
8%
Cognitive Disorders
25%
Cognitive Function
25%
Cognitive Neuroscience
33%
Control Theory
16%
Delusion
16%
Depressive Disorder
37%
Disinhibition
16%
Dopaminergic
18%
Executive Function
10%
Explicit Memory
16%
Face
16%
Functional Connectivity
16%
Functional Magnetic Resonance Imaging
12%
Gray Matter Volume
15%
Hippocampus
10%
Independent Component Analysis
8%
Individual Differences
18%
L-DOPA
18%
Late Life Depression
16%
Limb Movement
16%
Locus Coeruleus
50%
Longitudinal Study
16%
Magnetic Resonance Imaging
12%
Magnetization Transfer
9%
Memory System
8%
Mental Disorder
16%
Motor Control
41%
Negative Syndrome
53%
Nervous System Disorder
16%
Neuromelanin
8%
Neuroscience
48%
Norepinephrine
16%
Parkinson's Disease
83%
Placebo
12%
Positive Syndrome
16%
Prefrontal Cortex
16%
Pulse Pressure
16%
Short-Term Memory
8%
Striatum
8%
Structural Magnetic Resonance Imaging
8%
Supplementary Motor Area
66%
Temporal Lobe
16%
Treatment-Resistant Schizophrenia
16%
